Foley Hoag LLP is representing IQuum, Inc., a diagnostics technology company, in a proposed acquisition by Swiss drug maker Roche for approximately $450 million. The merger agreement is subject to various conditions, and once the transaction is complete, Roche plans to integrate IQuum into its Roche Molecular Diagnostics division.
Headquartered in Marlborough, MA, IQuum’s novel sample testing biological process allows minimally skilled users to rapidly extract critical information from biological samples. The lab-in-a-tube platform will meet the market needs for extracting comprehensive information from biological samples, and is developing the next generation of biological sample testing systems to deliver the achievements in genomics and biotechnology to healthcare and daily life.
The Foley Hoag team was led by Peter Rosenblum, Robert Warren and Adrienne Ellman with support from others at the firm, including associate Erin Kravitz providing transactional advice, partner Beth Arnold providing intellectual property advice, partners Nicola Lemay and Earl Mellott providing tax advice and partners Teresa Martland and Mike Rosen along with associate Kip Cawley providing executive compensation advice.